CLL1-CD33 cCART cell therapy (iCell Gene Therapeutics)

N/A

Report date: 2024/12/20 09:49:17

Base Information

Drug NameCLL1-CD33 cCART cell therapy (iCell Gene Therapeutics)
Drug Alias NameCLL1-CD33-cCAR
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionMyeloid cell surface antigen CD33 modulatorsC-Type lectin domain family 12 member A modulatorsImmunologic cytotoxicity +[5] 
TargetsC-Type lectin domain family 12 member AMyeloid cell surface antigen CD33
Therapy Area/IndicationsMyeloproliferative DisordersMyelodysplastic SyndromesHematologic Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesiCell Gene Therapeutics LLC
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesiCell Gene Therapeutics LLCiCar Bio Therapeutics Ltd
Active IndicationsN/A
Inactive IndicationsMyeloproliferative DisordersMyelodysplastic SyndromesHematologic Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksN/A